Australian biopharmaceutical company Propanc Biopharma has announced a significant strategic move, securing up to $100 million from a crypto-focused family office, Hexstone Capital. This funding will establish a crypto treasury aimed at accelerating the development of its lead cancer therapy, PRP, which is slated for human trials in late 2026. The company views this as a transformative step to strengthen its financial position and advance its oncology platform.